ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Immunic Licenses IMU-856 from Daiichi Sankyo americanpharmaceuticalreview
January 13, 2020Immunic announced its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo, has exercised its exclusive global option to license a group of compounds, designated by Immunic as IMU-856.
Pharma Sources Insight July 2025
